Corrigendum to "Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models" [Int. J. Pharm. 586 (2020) 119541]
Int J Pharm. 2025 Jan 13:125208.
doi: 10.1016/j.ijpharm.2025.125208.
Online ahead of print.
1 Laboratory of Drug Discovery and Design, School of Pharmacy, Liaocheng University, Liaocheng, Shandong 252000, PR China.
2 Joint Laboratory for Translational Medicine Research, Liaocheng People's Hospital, Liaocheng, Shandong 252000, PR China. Electronic address: [email protected].
3 Department of Pharmacy, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, PR China. Electronic address: [email protected].
4 The Institute for Tissue Engineering and Regenerative Medicine, Liaocheng University/ Liaocheng People's Hospital, Liaocheng, Shandong 252000, PR China.
5 Zhong Yuan Academy of Biological Medicine, Liaocheng People's Hospital, Liaocheng, Shandong 252000, PR China.
6 Laboratory of Drug Discovery and Design, School of Pharmacy, Liaocheng University, Liaocheng, Shandong 252000, PR China. Electronic address: [email protected].